Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Subjects who participated in study 580299-007.~* Written informed consent obtained from the subject prior to enrollment.~Exclusion Criteria:~* Use or planned use of any investigational or non-registered product other than the study vaccine.~* Decoding of the subject's 580299-001 treatment allocation to either the subject or the investigator.~* Administration or planned administration of any other HPV vaccine, other than the vaccine administered in study 580299-001.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
- Placebo Group (Type: PLACEBO_COMPARATOR): Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.

Based on this trial design, predict the completion outcome and termination type (if applicable).